Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Cash from Financing Activities: 2012-2024

Historic Cash from Financing Activities for Akebia Therapeutics (AKBA) over the last 13 years, with Dec 2024 value amounting to $49.7 million.

  • Akebia Therapeutics' Cash from Financing Activities fell 8.99% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.1 million, marking a year-over-year increase of 284.29%. This contributed to the annual value of $49.7 million for FY2024, which is 297.03% up from last year.
  • Per Akebia Therapeutics' latest filing, its Cash from Financing Activities stood at $49.7 million for FY2024, which was up 297.03% from -$25.2 million recorded in FY2023.
  • Over the past 5 years, Akebia Therapeutics' Cash from Financing Activities peaked at $231.7 million during FY2020, and registered a low of -$25.2 million during FY2023.
  • For the 3-year period, Akebia Therapeutics' Cash from Financing Activities averaged around $13.0 million, with its median value being $14.6 million (2022).
  • Per our database at Business Quant, Akebia Therapeutics' Cash from Financing Activities plummeted by 272.67% in 2023 and then skyrocketed by 297.03% in 2024.
  • Over the past 5 years, Akebia Therapeutics' Cash from Financing Activities (Yearly) stood at $231.7 million in 2020, then tumbled by 42.29% to $133.7 million in 2021, then slumped by 89.08% to $14.6 million in 2022, then slumped by 272.67% to -$25.2 million in 2023, then surged by 297.03% to $49.7 million in 2024.